Skip to content

Author

Carolyn S. P. Lam

We have 3 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial.

In ambulatory patients with HFrEF receiving contemporary GDMT, it is not convincing evidence that the neutral effect of vericiguat on cardiovascular death or first HF hospitalization was modified by GDMT class, dose attainment, or overall intensity, in a cohort with very high background GDMT use and limited power for i...

Justin A. Ezekowitz, J. Butler, Derek Cyr et al. · 0 citations

HFpEF in Asia Distinct Phenotypes, Shared Mechanisms, and Emerging Insights

Mechanistically, visceral adiposity, systemic inflammation, immunometabolic dysregulation, structural remodeling, and accelerated cardiac aging converge to drive HFpEF across Asian patients, often at lower body mass index thresholds than recognized in Western models.

E. Balasa, F. Capone, A. Vacca et al. · 0 citations
Review Open access Aug 2026

HFpEF in Asia: Distinct Phenotypes, Shared Mechanisms, and Emerging Insights.

Mechanistically, visceral adiposity, systemic inflammation, immunometabolic dysregulation, structural remodeling, and accelerated cardiac aging converge to drive HFpEF across Asian patients, often at lower body mass index thresholds than recognized in Western models.

E. Balasa, F. Capone, A. Vacca et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.